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Interstitial cystitis (IC) is a heterogeneous syndrome characterized by bladder pain and is associated with
frequency and nocturia. Research ﬁndings have proposed several pathophysiological mechanisms
including epithelial dysfunction, activation of mast cells, neurogenic inﬂammation, autoimmunity, and
occult infection. One of the most common ﬁndings in IC bladders is denudation or thinning of the
bladder epithelium, suggesting an altered regulation of urothelial homeostasis. Different phenotypes of
IC have been explored including Hunner and nonHunner type IC (ulcer and nonulcer type IC), hyper-
sensitive bladder, and bladder pain with and without functional somatic syndrome. Different gene ex-
pressions have been found in different IC phenotypes. Augmented purinergic signaling in the bladder has
been found in IC. Signiﬁcant increases in antiproliferative factor, decreases in heparin-binding epidermal
growth factor, and increased levels of epidermal growth factor have been discovered. Abnormal cytokine
secretion in IC bladders has also been related to an increase in purinergic signaling, which mediates
increased bladder sensation. Abnormal expression of uroplakins, chondroitin sulfate, junction protein E-
cadherin, and tight junctional protein zonula occludens-1, strongly suggests abnormal epithelial differ-
entiation in IC bladders. The increased apoptosis of urothelium has been associated with increased
tryptase activity and clinical bladder pain scores, suggesting chronic inﬂammation, increased apoptosis,
and abnormal urothelial function are closely associated in IC bladders. A local inﬂammatory process
might be induced through the afferent and efferent nerves in the suburothelial interstitial cellular
network, which integrates the transmission of signals from the urothelium to the detrusor muscles in the
bladder wall. These urothelial dysfunctions can be partially reversed after repeated bladder injections of
botulinum toxin A. Multiple comorbidities and functional somatic syndromes are also found to associate
with IC, together with increased sympathetic nervous system tonicity and increased serum proin-
ﬂammatory proteins and cytokines. Thus, the pathogenesis of IC might be involved in systemic disorders.
It is possible to postulate that the pathophysiology of IC might evolve sequentially by: (1) urothelial
injury (urinary tract infection, surgical trauma, chronic bladder overdistention); (2) suburothelial
inﬂammation; (3) chronic inﬂammatory cell inﬁltration in the suburothelium; and (4) increased in-
ﬂammatory reaction in the sensory afferents, dorsal horn ganglia, and corresponding spinal cord. IC
might be considered a progressive disease that evolves from early stage to late stage bladder conditions.
Insult to the visceral organ initiates an inﬂammatory process, causing urothelial dysfunction in the
bladder. The inﬂammatory reaction proceeds along the sensory nerves in the dorsal root ganglion as well
as the sacral cord. The sensory impulses also ascend to the corresponding cortical gyrus. Patients might
have an early inﬂammatory reaction and produce characteristic IC symptoms, including bladder pain,
urgency, frequency, and a positive potassium chloride sensitivity test. If the insult does not continue, the
inﬂammation resolves and patients may have symptom relief after symptomatic treatment. However, if
the bladder insult continues, the inﬂammatory reaction increases to a higher level, causing permanent
inﬂammation printing.
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quency, and nocturia. There is no clear deﬁnition of IC as the clinical
symptoms and histology are not speciﬁc. The diagnosis of IC can
only bemade based on a combination of a thorough patient history,
sterile and cytologically negative urine, cystoscopic hydro-
distention under anesthesia, and bladder biopsy. Many different
etiologies have been proposed including: (1) a postinfection auto-
immune process; (2) mast cell activation induced by inﬂammation,
toxins, or stress; (3) urothelial dysfunction and increased perme-
ability of the urothelium; and (4) neurogenic inﬂammation. How-
ever, none of these etiologies has been deﬁnitely proven [1]. This
review highlights recent research ﬁndings in the pathophysiology
of IC/bladder pain syndrome (BPS).
2. Urothelial barrier dysfunction
Recent ﬁndings have proposed several pathophysiological
mechanisms for IC, including epithelial dysfunction, activation of
mast cells, neurogenic inﬂammation, autoimmunity, and occult
infection [2]. One of the most common ﬁndings in bladder mucosal
biopsies from IC patients is denudation or thinning of the bladder
epithelium, suggesting an altered regulation of urothelial homeo-
stasis [3].
The urothelium of the urinary bladder acts as a barrier between
urine and its solutes and the underlying bladder. Bladder surface
mucus is a critical component of this function [4e6]. Glycosami-
noglycans (GAG) are extremely hydrophilic and trap water at the
outer layer of the umbrella cell. In patients with IC, disruption of the
urothelial barrier may initiate a cascade of events in the bladder,
leading to symptoms and disease. Urothelial barrier dysfunction
leads to the migration of urinary solutes, in particular, potassium,
which depolarizes nerves and muscles and causes tissue injury
[7,8].
The urothelium plays an important role in communicating with
bladder nerves, smooth muscle, immune cells, and inﬂammatory
systems [5]. A leaky epithelium has been considered the primary
disease that causes urinary potassium leakage into the sub-
urothelium and generates symptoms of frequency urgency and
bladder pain [9,10]. Intravesical potassium chloride instillation at a
concentration of 0.4M was found to provoke symptoms in 4.5% of
healthy people, 70% of patients with IC, 18% of IC patients treated
with heparin, and 100% of patients with irradiation cystitis [6]. A
positive potassium stimulation test causing an increase in bladder
pain of  2 on a visual analogue scale and a small cystometric ca-
pacity were found to be 100% predictive of IC in patients with hy-
persensitive bladder syndrome [11]. Intravesical sulfated
polysaccharide was found to restore injured urothelium to normal
[12]. A recent study demonstrated that intravesical GAG replen-
ishment therapy also produces a physiological effect of decreasing
recruitment of inﬂammatory cells in an acute damaged bladder rat
model [13].
A subset of patients with IC might have a failure of urothelial
cytodifferentiation, which might contribute to the disease and
bladder dysfunction [4]. Abnormal expression of molecular
markers has been found in IC bladder biopsies. Abnormal expres-
sion of uroplakins, chondroitin sulfate, and tight junctional protein
zonula occludens-1 (ZO-1) strongly suggests abnormal differenti-
ation in bladders with IC, whereas elevated E-cadherin expression
may represent an adaptation to increased bladder permeability
[14].
Recent studies have shown increased apoptosis of the urothe-
lium in patients with IC. Terminal deoxynucleotidyl transferasemicrovascular endothelial cells but not in the endothelial cells of
venules in IC bladders [15]. Higher levels of urothelial cell apoptosis
and abnormal E-cadherin expression in IC bladders were associated
with chronic inﬂammation [16]. Bladder epithelial cells from pa-
tients with IC exhibited profoundly decreased proliferation [16].
The proliferation rate of explanted bladder epithelial cells from
patients with IC was signiﬁcantly decreased compared to that of
control cells, indicating an intrinsic abnormality in IC cell prolifer-
ation. This abnormality may be caused by an antiproliferative factor
(APF), which induces reversible inhibition of heparin-binding
epidermal growth factor-like (HB-EGF-like) growth factor produc-
tion and normal bladder epithelial cell proliferation [17]. APF
treatment caused signiﬁcant increases in the paracellular perme-
ability of normal bladder epithelial cell monolayers and the
attenuation of tight junctions compared with mock APF, similar to
changes seen in IC cells. APF treatment also decreased expression of
the tight junction proteins ZO-1 and occludin [18,19]. These results
are consistent with previous reports. In patients with IC, increased
levels of cleaved caspase-3, Fas, and cleaved caspase-8 were found,
suggesting activation of the extrinsic apoptotic pathway [20].
3. Chronic inﬂammation of the suburothelium in IC
Most urologists consider IC a result of long-standing inﬂam-
mation of the bladder [3]. Bladder histological analysis shows in-
ﬁltrates of mast cells, eosinophilic leukocytes, and T-lymphocytes,
suggesting IC is mediated by the immune system [21]. Biopsies of IC
bladders have conﬁrmed the involvement of eosinophils, macro-
phages in the urothelium, and mast cells in the detrusor. Involve-
ment of eosinophils is also supported by urine cytology showing
increased urinary eosinophil cationic protein in the urine [22,23].
Our previous study found increased serum immunoglobulin E
levels in patients with ketamine cystitis [24]. However, the
participation of immunoglobulin E-mediated inﬂammation in the
pathogenesis of the bladder inﬂammation in IC has not been
investigated. Mast cells have been considered crucial effector cells
for the immune response implicated in the pathogenesis of IC [21].
High expression of T- and B-cell markers, low expression of uro-
thelial markers, focal lymphoid aggregates in the submucosa, and
high immunoglobulin concentrations in the urine were found in
patients with IC European Society for the Study of Interstitial
Cystitis type 3C [25]. A recent study showed that suburothelial mast
cell distribution was characteristic of IC with Hunner's lesions,
whereas detrusor mastocytosis had a poor predictive value for IC
[26].
Chronic suburothelial inﬂammation might inhibit normal basal
cell proliferation and affect apical urothelial function. Treatment of
urothelial dysfunction cannot be based solely on replacement of
defense glycoproteins in the bladder urothelium. Furthermore,
bladder inﬂammation caused by intravesical irritants or that in
patients with IC leads to acute afferent nerve activity and long-term
plasticity that lowers the threshold for nociceptive and mechano-
ceptive afferent ﬁbers [27,28]. A rise in bladder nerve growth factor
(NGF) in the muscle or urothelium initiates signals that are trans-
ported along the afferent nerves of the bladder to the dorsal root
ganglion or spinal cord [29,30].
Previous studies showed that intravesical injection of botulinum
toxin A (BoNT-A) reduced bladder pain in patients with refractory
IC [31,32]. NGF mRNA levels in the bladder tissue signiﬁcantly
increased in patients with IC and decreased to the normal range
after BoNT-A treatment [33]. Repeated BoNT-A injections plus
hydrodistention might provide a better outcome in treating IC
compared with hydrodistention alone. Urothelial apoptosis and E-
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repeated BoNT-A injections, and this was associated with a reduc-
tion in bladder pain scores [34]. Chronic suburothelial inﬂamma-
tion might alter urothelial function and cell differentiation, and
BoNT-A injections might reduce inﬂammation and restore a
healthy urothelium, thereby improving the clinical symptoms of IC.
Previously published results conﬁrm that IC involves an aber-
rant differentiation program in the bladder urothelium that leads to
altered synthesis of several proteoglycans, cell adhesion and tight
junction proteins, and bacterial defense molecules such as GP51.
Therefore, replacement therapy with GAG has beenwidely used for
treatment of IC [35]. However, further correlation of the expression
of the proteoglycan core proteins and differentiation-related
markers with inﬂammation scores in IC bladder biopsies revealed
that the abnormalities in urothelial differentiation and loss of
barrier function in IC were independent of inﬂammation [22].
4. Glomerulations in the bladder urothelium in IC
In previous reports, histological evidence showed several
marked changes in various tissue elements. Firstly, abnormal
behavior of urothelial cells disrupted the permeability barrier.
Secondly, the vascular lesions included endothelial cell injury and
suggested a slowmicrocirculation. Thirdly, neural changes included
a combination of degenerative and regenerative features [36,37].
Several important proteins associated with bladder inﬂamma-
tion were associated with increased angiogenesis and glomer-
ulations in IC. Glomerulations during cystoscopic hydrodistention
were highly associated with overexpression of angiogenic growth
factors such as platelet derived endothelial cell growth factor/
thymidine phosphorylase [38], vascular endothelial growth factor
(VEGF) [36], and hypoxia-inducible factor-1-alpha [39]. Measuring
the urine concentrations of these angiogenic growth factors may be
a new and useful method for the diagnosis of IC.
VEGF plays a key role in bladder inﬂammation and is closely
associated with the vascular alterations observed in patients with
IC. Increased VEGF was associated with bladder inﬂammation and a
small functional bladder capacity in IC patients. VEGF decreased
after repeated BoNT-A injections [40].
5. Neurogenic inﬂammation in IC/PBS and central nervous
sensitization
There is increasing evidence for the role of neurogenic inﬂam-
mation in the pathophysiology of several diseases, including
asthma, arthritis, migraine, and, possibly, IC [41]. Preliminary
studies have shown an increase in levels of immunoreactive sub-
stance P and NGF in the bladder tissue and urine [42,43]. P2X3
receptors have also been shown to localize on the suburothelial C-
ﬁbers and detrusor muscles, and colocalize with other sensory re-
ceptors, such as transient receptor potential vanilloid receptors,
euokinin receptor 1, calcitonin-gene receptor protein, tyrosin ki-
nase A, and other sensory-related receptors [44]. IC was found to
associate with increased urinary adenosine triphosphate (ATP) and
increased stretch-activated ATP release by bladder urothelial cells,
suggesting augmented purinergic signaling in the bladder [45]. Any
insult to the urothelium or directly to the bladder wall may induce a
cascade of inﬂammatory reactions and produce painful inﬂamma-
tion, such as in IC [46].
The chronic pain symptomatology in IC may also be due to
central nervous system sensitization and persisting abnormality or
activation of the afferent sensory system in the urinary bladder
[47]. Increased central c-fos expression has been demonstrated in
animal models of neurogenic detrusor overactivity and chronic
inﬂammation. Elimination of rat spinal neurons expressingeuokinin receptor 1 receptors reduced bladder overactivity and
spinal c-fos expression induced by bladder irritation [48,49]. If the
neurogenic inﬂammation in the dorsal root ganglia can be elimi-
nated gradually through intravesical treatment, the visceral pain in
IC can thus be relieved.
The afferent system in the bladder plays an important role in
lower urinary tract dysfunction [50]. The symptoms of sensory
urgency were associated with the increased expression of transient
receptor potential vanilloid receptors mRNA in the trigone mucosa
[51]. There was a signiﬁcantly greater release of ATP following
mechanical stretch of the urothelium from IC bladders [52]. Me-
chanical stimulus in IC patients induced a signiﬁcantly higher
stimulus-response curve, and a segmental hyperalgesia was noted,
suggesting spinal central sensitization was involved in IC patho-
physiology [53].
There is increasing evidence showing that afferent hyperexcit-
ability is a result of neurogenic bladder inﬂammation [54]. Over-
expression of NGF in mouse urothelium leads to neuronal
hyperinnervation, referred somatic pelvic sensitivity, elevatedmast
cells, and changes in bladder function [55]. Women with bladder
oversensitivity in the absence of urinary tract infection (UTI) had a
signiﬁcantly lower median voided volumes at a strong desire to
void and maximal cystometric capacity than controls, suggesting
an increased hypersensitivity [56]. Increased urothelial cell
apoptosis, increased mast cell counts, and lower junctional protein
E-cadherin were noted in women with recurrent UTI. These uro-
thelial dysfunctions might explain the hypersensitivity symptoms
in women after recurrent UTI [57]. A recent study suggested IC
might bemediated by factors including changes in the properties of
peripheral bladder afferent pathways responding to normally
innocuous stimuli [58].
6. Alteration of urothelial factors and cytokines in IC/BPS
bladders
APF is a small glycoprotein made speciﬁcally by bladder
epithelial cells in patients with IC which induces changes in
expression of certain epithelial cell proteins and profoundly in-
hibits cell growth. APF may affect the increased permeability and
decreased tight junction formation of bladder epithelial cells and
contribute to the urothelial leak and bladder pain symptoms seen
in IC [18,59]. Signiﬁcant increases in APF, decreases in HB-EGF, and
increased levels of EGF were discovered in the urine samples of
patients with IC [60]. Microarray analysis indicated that APF can
also induce changes in the pattern of cellular gene expression to-
ward a more differentiated phenotype [60]. Previous results indi-
cate that APF treatment causes signiﬁcant increases in the
paracellular permeability of normal bladder epithelial cell mono-
layers and the attenuation of tight junctions compared with mock
APF, similar to changes seen in IC cells. APF may contribute to the
leakiness of the bladder epithelial barrier seen in IC [61]. Antagonist
of APF signiﬁcantly increased mRNA expression of ZO-1, occluding,
and claudin 1, claudin 4, claudin 8, and claudin 12 in IC cells,
normalized epithelial cells, and decreased paracellular perme-
ability [62].
The human bladder urothelium and urothelial cells play
important roles in the normal defense mechanism. APF expressed
by the urothelial cells induces increased permeability in cell cul-
tures, and regulates expression of other cytokines, including
upregulation of HB-EGF and down-regulation of EGF. These cyto-
kine abnormalities are also related to increases in purinergic
signaling, which mediates increased bladder sensation. Alterations
of uroplakins, glycoproteins expressed only in the apical urothelial
cells, may result in bladder symptoms related to increased
permeability or decreased protective function [63]. The abnormal
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core proteins is independent of inﬂammation, further suggesting
different subtypes of IC [21].
7. Urinary nerve growth factor and inﬂammatory cytokines in
IC/BPS
IC involves an aberrant differentiation program in the bladder
urothelium that leads to altered synthesis of several proteoglycans,
cell adhesion, tight junction proteins, and bacterial defense mole-
cules such as GP51. These ﬁndings led to the rationale for searching
for potential clusters of urinary biomarkers to detect IC in patients
with overactive bladder (OAB) and frequency urgency syndrome
[64].
In the urinary tract, NGF is produced by bladder smoothmuscles
and the urothelium [65]. NGF is also involved in ongoing regulation
of neural function in conditions such as spinal cord injury and
denervation, as well as in inﬂammation and pain [2,65,66].
Increased levels of NGFwere also reported in the bladder tissue and
urine of patients with sensory urgency and IC [43,67]. Intravesical
injections of BoNT-A reduced bladder pain in patients with re-
fractory IC [33]. NGF levels decreased to the normal range after
BoNT-A treatment [68]. However, urine NGF is also increased in
several lower urinary tract conditions such as UTI, bladder outlet
obstruction, and urinary tract stones [67]. Urinary NGF levels are
closely related to visual analog scores for pain and response to
conventional treatment for IC [69,70]. A decrease in the urinary
NGF level was associated with greater pain reduction and a suc-
cessful response to treatment, suggesting that urinary NGF levels
could be a useful biomarker for the severity of the bladder condi-
tion in patients with IC [69].
Urinary inﬂammatory mediators have been investigated as
noninvasive markers to identify IC [70]. Interleukin (IL)-6 levels
increased in the urine samples of IC patients and were positively
associated with pain scores [71]. Nonetheless, IL-6 was only
detected in the urine samples of patients with severe IC, but not
those with mild IC [72]. Both IL-6 and IL-8 levels were elevated in
patients with active IC [73], but similar levels were found in pa-
tients who met or did not meet the National Institute of Diabetes
and Digestive and Kidney Disorders criteria for IC [74]. IL-8 is an
important normal urothelial growth factor and is necessary for
normal urothelial cell survival in vivo and in vitro. Lower IL-8
expression levels contribute to the pathophysiology of IC [75]. A
combination of several particular elevated cytokines in the urine
raises the diagnostic rate for IC and might differentiate IC from
noninﬂammatory bladder conditions.
8. Systemic involvement in the pathogenesis of IC/BPS
Chronic inﬂammation is implicated in the development of OAB
and IC. Elevation of serum C-reactive protein (CRP) levels is asso-
ciated with chronic inﬂammation and lower urinary tract symp-
toms. Serum CRP levels were signiﬁcantly higher in patients with
OAB and IC than in control individuals [76]. Nevertheless, serum
CRP levels could be used to identify IC in patients with irritating
bladder symptoms and those refractory to antimuscarinic therapy.
Serum NGF was also found to be elevated in IC patients. The
mean serum NGF level was higher in patients with IC than control
individuals. No signiﬁcant correlation was found between the
serum and urinary NGF levels in IC patients. The clinical charac-
teristics and medical comorbidities did not show signiﬁcant dif-
ferences between IC patients with high and low serum NGF levels
[77]. These ﬁndings suggest that IC might be a heterogeneous
syndrome involving bladder-conﬁned inﬂammation or systemic
inﬂammation.Cytokines and chemokines play crucial roles in the pathogenesis
of several chronic inﬂammatory diseases. The upregulated proﬁle
of serum IL-1b, IL-6, tumor necrosis factor-a (TNF-a), and IL-8 in IC
patients could potentially have a prognostic role and/or serve as a
tool in choosing a proper therapeutic agent for treatment. Serum
proinﬂammatory cytokine (IL-1b, IL-6, and TNF-a) and chemokine
(IL-8) levels were signiﬁcantly higher in the sera of patients with IC
than controls [78]. A signiﬁcant correlation was found between IL-
1b and IL-8, IL-6 and CRP, IL-6 and IL-8, and IL-6 and TNF-a in serum
samples from IC/BPS patients. Increased expression of proin-
ﬂammatory cytokine (IL-1b, IL-6, and TNF-a) and chemokine (IL-8)
levels in the serum of IC patients implies not only mast cell acti-
vation, but also the possible important roles of some other in-
ﬂammatory mediators in the pathogenesis of IC.
Nickel et al [79] recently proposed a phenotyping system, called
UPOINT, to classify women with IC according to clinically relevant
urinary, psychosocial, organ speciﬁc, infection, neurological/sys-
temic, and tenderness domains. Increased symptom duration led to
a greater number of domains, and domains that functioned outside
of the bladder predicted a signiﬁcant impact on symptoms. IC pa-
tients reported more pain than controls in all reported body areas.
The increased pain phenotype was associated with poorer psy-
chosocial adjustment and diminished physical quality of life [80].
IC patients have higher odds of comorbid neurological diseases,
rheumatological diseases, and mental illnesses [81]. Patients with
functional somatic syndrome are at risk of IC [82]. Functional somatic
syndromes are risk factors for hysterectomy in patients with early
symptoms of IC [83]. A distinct phenotype of patients with IC and
associated multiple sensitivities with conﬁrmed allergies/sensitiv-
ities to medications and environmental factors has been identiﬁed
[84]. Myofascial pain was demonstrated in 78.3% of IC patients with
at least one trigger point, and 67.9% of patientswith numerous trigger
points [85]. Patients with the “pelvic pain beyond” phenotype re-
ported a higher prevalence of irritable bowel syndrome and ﬁbro-
myalgia, and more general fatigue and psychiatric conditions [86].
Sympathetic nervous system dysfunction is common in IC [87].
Noradrenaline levels in the blood at resting conditions and in 24-
hour urine samples were signiﬁcantly higher in IC/BPS patients
[88]. IC patients had diminished vagal activity and a shift towards
sympathetic nervous system dominance [89]. IC patients with
typical cystoscopic ﬁndings showed a marked autonomic response
(increase in heart rate, systolic and diastolic blood pressure) [90].
Different phenotypes of IC have been noted. IC European Society
for the Study of Interstitial Cystitis type 3C accounted for 55% of
cases. Patients with nonHunner disease were on average 20 years
younger, and had a signiﬁcantly larger maximum bladder capacity
than those with Hunner's disease [91]. Signiﬁcantly different mo-
lecular characteristics were found in IC patients with lower bladder
capacities [92].
DNA microarray analysis followed by quantitative real-time
polymerase chain reaction revealed overexpression of genes
related to immune and inﬂammatory responses in IC patients,
including T-helper type 1 related chemokines, and cytokines such
as CXCR3 binding chemokines, and TNF (ligand) superfamily,
member 14 (TNFSF14). These genes are potential biomarkers for IC
[93]. Gene expression analysis of urine sediment found that pa-
tients with Hunner lesions had increased proinﬂammatory gene
expression similar to that in a prior microarray bladder biopsy
study. However, the analysis failed to discriminate between pa-
tients with nonHunner IC and control individuals [94]. It is possible
to use quantitative proteomics and microarray analysis to identify
genes that are potentially regulated by APF with a low false dis-
covery rate. This molecular signature reﬂects the biological pro-
cesses of cell adhesion, cell proliferation, and inﬂammation,
constituting the pathophysiology of IC [95].
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From the above evidence, it is possible to postulate that the
pathophysiology of IC syndrome might evolve sequentially by: (1)
urothelial injury (UTI, surgical trauma, chronic overdistention); (2)
suburothelial inﬂammation; (3) chronic inﬂammatory cell inﬁltra-
tion in the suburothelium; and (4) increased inﬂammatory reaction
in the sensory afferents, dorsal horn ganglia, and corresponding
spinal cord.
IC might be considered a progressive disease that evolves from
early stage to late stage bladder conditions. Insult to the visceral
organ initiates an inﬂammatory process causing urothelial dysfunc-
tion in the bladder. The inﬂammatory reaction proceeds along the
sensory nerves in the dorsal root ganglion as well as the sacral cord.
The sensory impulse also ascends to the corresponding cortical gy-
rus. Patients might have an early inﬂammatory reaction and produce
characteristic symptoms of IC, including bladder pain, urgency, fre-
quency, and a positive potassiumchloride sensitivity test. If the insult
does not continue, the inﬂammation resolves and patients may have
symptom relief after symptomatic treatment. However, if the bladder
insult continues, the inﬂammatory reaction increases to a higher
level, causing permanent inﬂammation printing.References
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